Therapeutic antibodies: Discovery and development using the ProteOn XPR36 biosensor interaction array system

Analytical Biochemistry
Vered BronnerTsafrir Bravman

Abstract

Therapeutic monoclonal antibodies are becoming a significant and rapidly growing class of therapeutic pharmaceuticals. Their discovery and development requires fast and high-throughput methodologies for screening and selecting appropriate candidate antibodies having high affinity for the target as well as high specificity and low cross-reactivity. This study demonstrates the use of the ProteOn XPR36 protein interaction array system and its novel approach, termed One-Shot Kinetics, for the rapid screening and selection of high-affinity antibodies. This approach allows multiple quantitative protein binding analyses in parallel, providing association, dissociation, and affinity constants for several antibodies or supernatants simultaneously in one experiment. We show that the ProteOn XPR36 system is a valuable tool for use across multiple stages of the therapeutic antibody discovery and development process, enabling efficient and rapid screening after panning, affinity maturation, assay validation, and clone selection.

References

Sep 21, 2000·Pharmaceutical Science & Technology Today·D G Myszka, R L Rich
Jul 18, 2002·Nature Reviews. Drug Discovery·Matthew A Cooper
Jun 24, 2003·Drug Discovery Today·Martin J Glennie, Jan G J van de Winkel
Jan 31, 2004·Analytical Biochemistry·Gabriela A CanzianiDavid G Myszka
Sep 10, 2005·Nature Biotechnology·Hennie R Hoogenboom
Oct 28, 2005·Expert Review of Anticancer Therapy·Roy NoyYoram Reiter
Feb 17, 2006·Journal of Immunological Methods·Mieke SteukersMarc Vanhove
Mar 3, 2006·Analytical Biochemistry·Pär SäfstenDavid G Myszka
Mar 3, 2006·Analytical Biochemistry·Dina WassafDaniel J Sexton
Mar 16, 2006·Proceedings of the National Academy of Sciences of the United States of America·Greg A LazarBassil I Dahiyat
Sep 12, 2006·Analytical Biochemistry·Tsafrir BravmanDavid G Myszka
Nov 15, 2006·Current Pharmaceutical Design·Walter Huber, Francis Mueller
Nov 17, 2006·Nature Chemical Biology·Sachdev S Sidhu, Frederic A Fellouse
Nov 30, 2006·Drug Discovery Today·Matthew A Cooper
Dec 6, 2006·Analytical Biochemistry·Rebecca L Rich, David G Myszka
Dec 8, 2006·Expert Opinion on Biological Therapy·Germaine Fuh
May 5, 2007·Expert Opinion on Biological Therapy·Itai Benhar
Jan 10, 2008·Journal of Medicinal Chemistry·Anthony M GiannettiMichelle F Browner
Oct 28, 2008·Journal of Molecular Recognition : JMR·Rebecca L Rich, David G Myszka
Dec 30, 2008·Analytical Biochemistry·Yasmina N AbdicheJaume Pons
Feb 10, 2009·Current Medicinal Chemistry·P NieriA Podestà

❮ Previous
Next ❯

Citations

Jan 27, 2012·Analytical and Bioanalytical Chemistry·T F McGrathT L Fodey
Mar 1, 2012·Expert Reviews in Molecular Medicine·Rony Dahan, Yoram Reiter
Oct 20, 2012·Journal of Structural Biology·Weimin WuAlasdair C Steven
Aug 3, 2013·Analytical Biochemistry·Francisco YleraAchim Knappik
May 7, 2013·The Analyst·Marimuthu CitartanThean-Hock Tang
Nov 2, 2014·The Journal of Immunology : Official Journal of the American Association of Immunologists·Ravit OrenYoram Reiter

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex, associated with a generally dismal prognosis owing to its aggressive behavior. Here are the latest discoveries pertaining to this disease.

Biosensors for Cancer Detection

Biosensors are devices that are designed to detect a specific biological analyte by essentially converting a biological entity (ie, protein, DNA, RNA) into an electrical signal that can be detected and analyzed. The use of biosensors in cancer detection and monitoring holds vast potential. Biosensors can be designed to detect emerging cancer biomarkers and to determine drug effectiveness at various target sites. Biosensor technology has the potential to provide fast and accurate detection, reliable imaging of cancer cells, and monitoring of angiogenesis and cancer metastasis, and the ability to determine the effectiveness of anticancer chemotherapy agents.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.